Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Cytokinindusert minnelignende NK-celleadoptiv terapi etter haploidentisk donorhematopoietisk celletransplantasjon

26. august 2026 oppdatert av: Washington University School of Medicine

En fase II-studie av cytokinindusert minnelignende NK-celleadoptiv terapi etter haploidentisk donorhematopoietisk celletransplantasjon

This is a standard phase 2 study powered to demonstrate improvement in the 100 day leukemia free survival to 30% from <10% expected with the use of reduced intensity haplo-HCT in this extremely high-risk patient cohort (based on the institutional experience using non-myeloablative / reduced intensity conditioning in a similar patient cohort).

A formal safety evaluation will be done after every 6th patient enrolled and the trial will be stopped if noted to have unusually higher engraftment failure (acute GVHD rates (>60% any grades or >30% grade III/IV or ≥ 50% severe cGVHD) or engraftment failure rates (≥15%).

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

60

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Missouri
      • St Louis, Missouri, Forente stater, 63110
        • Washington University School of Medicine

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Recipient Inclusion Criteria:

  • Refractory AML without complete remission (CR) after 2 or more cycles of induction therapy (primary induction failure), or AML relapsed after obtaining a CR and failed one or more cycles of re-induction therapy. Standard dose 10-day decitabine (20 mg/m2 daily IV x 10 days) or 7-day azacitidine (75-100 mg/m2 daily SC/IV x 7 days) will be considered as one cycle of induction therapy.

  • At least 18 years of age

  • Available HLA-haploidentical donor that meets the criteria in the protocol

  • Patients with known CNS involvement with AML are eligible provided that they have been treated and CSF is clear for at least 2 weeks prior to enrollment into the study. CNS therapy (chemotherapy or radiation) should continue as medically indicated during the study treatment.

  • Karnofsky performance status > 60 %

  • Adequate organ function as defined below:

    • Total bilirubin < 2 mg/dl
    • AST(SGOT)/ALT(SGPT) < 3.0 x IULN
    • Creatinine within normal institutional limits OR creatinine clearance > 60 mL/min/1.73 m2 by Cockcroft-Gault Formula
    • Oxygen saturation ≥90% on room air and adjusted DLCO of at least 40%
    • Ejection fraction ≥40%
  • Able to be off of corticosteroids (10 mg or less of prednisone or equivalent doses of other systemic steroids are allowed) and any other immune suppressive medications beginning on Day -3

  • Women of childbearing potential must have a negative pregnancy test within 28 days prior to study registration. Female and male patients (along with their female partners) must agree to use two forms of acceptable contraception, including one barrier method, during participation in the study and throughout the DLT evaluation period.

  • Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

Recipient Exclusion Criteria:

  • Relapsed after allogeneic transplantation.
  • Circulating blast count >30,000/uL by morphology or flow cytometry (cyto-reductive therapies including leukapheresis or hydroxyurea are allowed).
  • Uncontrolled bacterial or viral infections, or known HIV, Hepatitis B or C infection.
  • Presence of donor specific antibodies (DSA) with Mean Fluorescence Intensity (MFI) of >5000 as assessed by the single antigen bead assay, < 6 weeks prior to starting transplant conditioning
  • Uncontrolled angina, severe uncontrolled ventricular arrhythmias, or EKG suggestive of acute ischemia or active conduction system abnormalities.
  • New progressive pulmonary infiltrates on screening chest x-ray or chest CT scan that have not been evaluated with bronchoscopy. Infiltrates attributed to infection must be stable/ improving after 1 week of appropriate therapy (4 weeks for presumed or proven fungal infections)
  • Known hypersensitivity to one or more of the study agents
  • Received any investigational drugs within the 14 days prior to the first day of transplant conditioning
  • Pregnant and/or breastfeeding

Donor Inclusion Criteria:

  • Related donor (sibling, offspring, or offspring of sibling)
  • At least 18 years of age
  • HLA-haploidentical donor/recipient match by at least Class I serologic typing at the A&B locus.
  • In general good health, and medically able to tolerate leukapheresis required for harvesting the NK cells for this study.
  • Ability to understand and willingness to sign an IRB approved written informed consent document

Donor Exclusion Criteria:

  • Positive for hepatitis, HTLV, or HIV infection
  • Pregnant and/or breastfeeding

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Recipient
  • Standard of care reduced conditioning regimen on Day -1
  • Graft cell infusion on Day 0
  • Post-transplant cyclophosphamide on Days +3 and +4
  • GvHD prophylaxis with tacrolimus and mycophenolate mofetil (MMF) will start on Day +5. MMF will continue till Day +35 and tacrolimus till Day +180 in the absence of GvHD
  • G-CSF will start on Day +7 and will continue until neutrophil engraftment as per institutional guidelines
  • The cytokine-induced memory like natural killer (CIML NK) cells will be infused on Day +7 without a filter or pump, slowly by gravity over at least 15 minutes.
  • ALT-803 will start approximately 4 hours after the CIML NK cell infusion. ALT-803 will be administered subcutaneously at a dose of 10 mcg/kg subcutaneously beginning Day +7 (on the day of CIML NK cell infusion) and then every 21 days for a total of 4 doses

-Day 0

Andre navn:
  • HCT

-GVHD prophylaxis

Andre navn:
  • Prograf

-GVHD prophylaxis

Andre navn:
  • CellCept
  • Myfortic

-Continue until neutrophil engraftment as per institutional guidelines

Andre navn:
  • Granulocytt-kolonistimulerende faktor

-Day +7

-Start approximately 4 hours after CIML NK cell infusion

Eksperimentell: Donor
  • Donors will receive subcutaneous G-CSF from Day -4 till Day 0 and undergo 20L apheresis per institutional guidelines.
  • Two consecutive days for collection are allowed in case of the target CD34+ cell dose being less than the target 4 x106/kg-bw from the first day of collection.
  • On Day +6 (one day before the planned CIML NK cell infusion), peripheral blood mononuclear cells will be collected by a single standard 20-L apheresis over 4-5 hours from the same haploidentical related donor that provided the HCT graft.

-Day +6

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Kaplan-Meier Estimate of Leukemia-free Survival Rate (LFS)
Tidsramme: 1 year post transplantation

-LFS is defined as the time from achievement of complete remission (CR) to the time of relapse, death in remission, or last follow-up.

1 year post transplantation

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Kaplan-Meier Estimate of Leukemia-free Survival Rate (LFS)
Tidsramme: 3 months post transplantation

-LFS is defined as the time from achievement of CR to the time of relapse, death in remission, or last follow-up.

3 months post transplantation
Kaplan-Meier Estimate of Overall Survival (OS)
Tidsramme: 1 year post transplantation

-OS is defined as the time from the date of Day 0 until death from any cause.

1 year post transplantation
Number of Recipients With Relapse Who Are Found to be CR (Complete Remission)
Tidsramme: Day 28 post transplantation

-CR: Morphologically leukemia free state (i.e. bone marrow with <5% blasts by morphologic criteria and no blasts with Auer rods, no evidence of extramedullary leukemia) and absolute neutrophil count ≥1000 /μL and platelets ≥100,000 /μL. Patient must be independent of transfusions.

Day 28 post transplantation
Complete Remission (CR) Rate
Tidsramme: Day 28 post transplantation

CR: Morphologically leukemia free state (i.e. bone marrow with <5% blasts by morphologic criteria and no blasts with Auer rods, no evidence of extramedullary leukemia) and absolute neutrophil count ≥1000 /μL and platelets ≥100,000 /μL. Patient must be independent of transfusions

Day 28 post transplantation

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Amanda Cashen, M.D., Washington University School of Medicine

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

30. januar 2017

Primær fullføring (Faktiske)

27. oktober 2025

Studiet fullført (Antatt)

13. februar 2028

Datoer for studieregistrering

Først innsendt

22. mai 2016

Først innsendt som oppfylte QC-kriteriene

22. mai 2016

Først lagt ut (Antatt)

25. mai 2016

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

21. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

26. august 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere